Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
Brandon Huffman, MD, is a medical oncologist in the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, where he treats patients with gastrointestinal (GI) cancers and leads clinical research developing better therapies.
Dr. Huffman embodies Dana-Farber’s mission as he develops clinical trials translating innovative laboratory ideas into novel treatment regimens improving outcomes for patients. In this work, he partners with laboratory scientists and is the lead investigator on several early-phase trials. He is currently focused on the development of novel immunotherapy combinations and targeted therapies in GI cancers.
Your support is instrumental to Dr. Huffman’s research in developing new treatments. Specifically, philanthropy supports areas that are difficult to fund through federal grants, such as collecting biopsies from patients, genetically sequencing biopsies, conducting molecular analyses, and hiring clinical trial personnel for the ongoing study activities. Thank you for your consideration and support.
Dr. Huffman is originally from Missouri. He received his Doctor of Medicine from the University of Missouri School of Medicine and completed his internal medicine residency at the Mayo Clinic in Rochester, Minnesota. He completed his fellowship in medical oncology at the Dana-Farber/Mass General Brigham Fellowship Program through where he was mentored by one of Dana-Farber’s expert clinician-investigators Dr. James Cleary and partnered with several Dana-Farber laboratory investigators like Drs. Alan D’Andrea, Andy Aguirre, Nilay Sethi, and Stephanie Dougan. Dr. Huffman has continued his collaboration with these laboratory- and physician-scientists since joining Dana-Farber Faculty.